Peter Lawrence, Cardurion Pharmaceuticals CEO

Car­du­ri­on touts Phase 2 da­ta for PDE9 in­hibitor in heart fail­ure, plans for two more tri­als

Car­du­ri­on Phar­ma­ceu­ti­cals tout­ed pos­i­tive da­ta for its heart fail­ure drug and an­nounced plans to pur­sue two more tri­als, three years af­ter the Mass­a­chu­setts biotech scored …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.